Arrowpoint Investment Partners (Singapore) Pte. Ltd. Argenx Se Transaction History
Arrowpoint Investment Partners (Singapore) Pte. Ltd.
- $487 Billion
- Q4 2024
A detailed history of Arrowpoint Investment Partners (Singapore) Pte. Ltd. transactions in Argenx Se stock. As of the latest transaction made, Arrowpoint Investment Partners (Singapore) Pte. Ltd. holds 634 shares of ARGX stock, worth $408,600. This represents 0.08% of its overall portfolio holdings.
Number of Shares
634Holding current value
$408,600% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding ARGX
# of Institutions
432Shares Held
29.2MCall Options Held
390KPut Options Held
272K-
Price T Rowe Associates Inc Baltimore, MD5.52MShares$3.56 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.07MShares$1.98 Billion3.02% of portfolio
-
Janus Henderson Group PLC London, X02.31MShares$1.49 Billion0.76% of portfolio
-
Capital World Investors Los Angeles, CA1.79MShares$1.15 Billion0.17% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$798 Million11.1% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $35.7B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...